NATERA INC (Common Stock) – ticker 45E (NTRA)
Natera (NTRA) Just Flashed Golden Cross Signal: Do You Buy?
After reaching an important support level, Natera (NTRA) could be a good stock pick from a technical perspective. NTRA surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
Natera, Inc. (NTRA) Q3 2024 Earnings Call Transcript
Natera, Inc. (NASDAQ:NTRA ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 AM ET Company Participants Mike Brophy - CFO Steve Chapman - CEO Alexey Aleshin - GM Oncology, CMO Conference Call Participants Puneet Souda - Leerink Partners Daniel Brennan - TD Cowen Tejas Savant - Morgan Stanley Rachel Vatnsdal - JP Morgan Douglas Schenkel - Wolfe Research Matthew Sykes - Goldman Sachs Tycho Peterson - Jefferies Operator Welcome to Natera's 2024 Third Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Natera (NTRA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Natera (NTRA) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Natera (NTRA) Reports Q3 Loss, Tops Revenue Estimates
Natera (NTRA) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.95 per share a year ago.
Natera And GeneDx: Outperforming Market Powered By Precision Medicines Tailwinds
The precision medicine market is projected to grow from $91.72 billion in 2024 to $246.3 billion by 2033, fueled by advancements in genomic technologies. In the last year, Natera, Inc. and GeneDx Holdings Corp. have outperformed the market and beaten analysts expectations. Natera's oncology tests driving revenue growth and GeneDx focusing on newborn rare disease diagnostics. Both firms have been improving financial metrics, with Natera showing strong revenue growth driven by oncology tests in Q2 2024, while GeneDx achieved profitability in Q3 2024.
All You Need to Know About Natera (NTRA) Rating Upgrade to Strong Buy
Natera (NTRA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Natera: Focus On Signatera And H1 2024 Results
Natera, Inc. is a diagnostic company focusing on cfDNA tests in women's health, organ health, and oncology. Natera's MRD test, Signatera, demonstrated strong growth, with a 64% increase in processed tests year-over-year, positioning it as the company's fastest-growing product. The liquid biopsy market is projected to grow at an 11% CAGR, with significant expansion in North America, supporting the long-term growth potential of Signatera.
Compared to Estimates, Natera (NTRA) Q2 Earnings: A Look at Key Metrics
The headline numbers for Natera (NTRA) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates
Natera (NTRA) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.97 per share a year ago.
Natera (NTRA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Natera (NTRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
